Skip to main content

Table 3 Factors associated with disease-free survival and overall survival in the cohort of propensity score-matched patients with ypT0-3N0 rectal cancer

From: Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery

  Disease-free survival Overall survival
Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Age, years   0.038   0.382   0.025   0.269
 < 70 1   1   1   1  
 ≥ 70 1.873 (1.036–3.386) 1.324 (0.706–2.483) 2.513 (1.125–5.609) 1.598 (0.695–3.673)
Sex   0.220     0.030   0.075
 Female 1     1 1 1  
 Male 1.553 (0.769–3.138)    4.951 (1.167–21.005) 3.782 (0.875–16.352)
Distance from AV (cm)   0.511     0.416   
 ≥ 10.0 1     1    
 5.0–9.9 0.669 (0.256–1.745)    0.510 (0.146–1.784)   
 < 5.0 0.956 (0.383–2.391)    0.897 (0.281–2.862)   
Differentiation   0.896     0.464   
 Well 1     1    
 Moderate 0.842 (0.411–1.726)    0.579 (0.233–1.439)   
 Poor, mucinous 0.871 (0.271–2.803)    0.868 (0.220–3.432)   
Pretreatment CEA (ng/mL)   0.014   0.039   0.348   
 < 5 1   1   1    
 ≥ 5 2.075 (1.156–3.727) 1.912 (1.033–3.540) 1.461 (0.662–3.226)   
Surgical procedure   0.039   0.339   0.033   0.225
 LAR 1   1   1   1  
 APR 2.133 (1.038–4.384) 1.465 (0.670–3.206) 2.615 (1.082–6.319) 1.764 (0.705–4.411)
Stage   0.003   0.019   0.002   0.007
 ypT0 1   1   1   1  
 ypT1 4.239 (1.299–13.831) 3.461 (1.017–11.778) 10.163 (2.033–50.817) 6.894 (1.343–35.381)
 ypT2 2.388 (1.040–5.485) 1.893 (0.808–4.434) 2.243 (0.555–9.059) 1.647 (0.387–7.005)
 ypT3 4.438 (1.963–10.032) 3.517 (1.528–8.093) 7.533 (2.114–26.848) 5.782 (1.588–21.051)
LN dissected   0.729     0.946   
 ≥ 12 1     1    
 < 12 0.901 (0.500–1.624)    1.028 (0.467–2.259)  
LVI/PNI   0.294     0.591   
 Negative 1     1    
 Positive 2.149 (0.516–8.955)   0.047 (0.000–3244.523)   
Margin   <0.001   0.001   <0.001   0.005
 Negative 1   1   1   1  
 Positive 8.956 (3.131–25.613) 7.193 (2.234–23.156) 10.375 (3.022–35.623) 7.035 (1.806–27.404)
Mandard regression grade   0.006     0.039   
 Grade 1 1     1    
 Grade 2 3.086 (1.319–7.222)    5.268 (1.398–19.860)   
 Grade 3 4.542 (1.880–10.970)    4.113 (0.920–18.379)   
 Grade 4 3.771 (1.263–11.261)    8.159 (1.825–36.482)   
Adjuvant chemotherapy   0.688     0.655   
 No 1     1    
 Yes 1.129 (0.626–2.035)    1.200 (0.539–2.669)   
  1. HR hazard ratio, CI confidence interval, AV anal verge, CEA carcinoembryonic antigen, LAR lower anterior resection, APR abdomino-perineal resection, LN lymph node, LVI lymphovascular invasion, PNI perineural invasion